CClinicalTrials.gg
Status unknownNCT05297006Updated Mar 25, 2022

Regulation and Mechanism of New Compound Functional Ingredients in Infants

An observational study in Sialic Acid and Oligosaccharide, sponsored by Peking University Third Hospital. Status unknown at 3 sites in China. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by Peking University Third Hospital · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Sex
All
01

Study summary

A prospective, multicentre, randomized, double-blind, parallel control study was conducted to analyze the changes in growth, intestinal flora, and immune function of infants with different feeding patterns from postnatal to 1 year of age.

Read the detailed description

Breast milk is the most beneficial and safe natural food for the growth and development of infants, but some mothers cannot complete breast feeding.For infants who cannot be breastfed, how to improve the composition of formula milk powder and improve the growth and development of infants is an important issue to be solved urgently in this field.It has been found that new compound functional ingredients oligosaccharides and sialic acid may be beneficial to the healthy growth and development of infants and young children, but the specific mechanism and significance are still unclear due to the lack of systematic research.Known as the "second Brain", the gut is connected to the Brain via the brain-gut-axis.Intestinal microecological status can significantly affect the development of infant nervous system and immune system, and then affect the occurrence of related diseases in adulthood.Oligosaccharides and sialic acid may affect the structure of intestinal microecology, protect the immune function of infants and promote the healthy development of infants.This project is based on the previous studies, using multicenter, prospective, randomized, double-blind, parallel-group trial, discussion of oligosaccharides and sialic acid in infants and young children the intestinal micro ecology and the regulation of immune function and the role mechanism, revealing the oligosaccharides and sialic acid in infants and young children the role of immediate and long-term growth, and the significance of these new type of composite function is added to the dairy ingredients, to research and development more accord with our country new dairy products provide theoretical basis for the healthy growth of infants and young children.

02

Conditions studied

  • Sialic Acid
  • Oligosaccharide

Keywords

  • Infant
  • Human milk
  • Growth and development
  • immune level
03

In context

Lead sponsor

Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Breastfeeding group The mother can breastfeed exclusively until the infants is at least 4 months old, after which complementary foods are added scientifically according to the baby's condition.

Formula group containing new compound functional ingredients Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.

Formula group containing new compound functional ingredients Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.

Inclusion criteria

  1. Healthy infants;
  2. Full-term (gestational age ≥37 weeks);
  3. Birth weight 2500-4500g;
  4. Mothers have no history of diabetes, hypertension, heart disease, and other diseases during pregnancy;
  5. The guardian signed informed consent and voluntarily enrolled into the group and promised to complete systematic follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Hospitalization with cognitive impairment or deformity ≥2 days
  2. History of birth asphyxia (Apgar score \< 3)
  3. Severe allergy to milk and serious medical conditions such as intracranial hemorrhage, chronic diarrhea, necrotizing colitis, or acute infection
  4. The guardian refused to enroll or could not complete the system follow-up.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Breastfeeding group

    The mother can breastfeed exclusively until the infants is at least 4 months old, after which complementary foods are added scientifically according to the baby's condition.

  • Formula group containing new compound functional ingredients

    Only use formula milk powder containing oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.

    Dietary Supplement: The infants who drank milk powder were given a dietary intervention four months before

  • Formula group without new compound functional ingredients

    Only use formula milk powder without oligosaccharides, sialic acid and other ingredients feed the infants for at least 4 months, and then complementary food is added scientifically according to the infant's condition.

    Dietary Supplement: The infants who drank milk powder were given a dietary intervention four months before

Interventions

  • Dietary supplementThe infants who drank milk powder were given a dietary intervention four months before

    The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients

06

What researchers measure

Primary outcomes

  1. Growth and development indexes

    Baby body length, weight, head circumference gain

    Time frame: 12 months

  2. Growth and development indexes

    Baby body weight gain

    Time frame: 12 months

  3. Growth and development indexes

    Baby body head circumference gain

    Time frame: 12 months

  4. Neurodevelopmental level

    The Peabody scale was used to assess the level of neural development of infants at 4 months and 6 months

    Time frame: 4 months

  5. Neurodevelopmental level

    The Peabody scale was used to assess the level of neural development of infants at 6 months

    Time frame: 6 months

07

Study locations

3 sites
  • Peking University People's Hospital
    Beijing, Beijing 100191, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Peking University First Hospital
    Beijing, 100191, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05297006
Lead sponsor
Peking University Third Hospital
Collaborators
Peking University First Hospital, Peking University People's Hospital
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
Apr 1, 2022 (estimated)
Primary completion
Oct 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Mar 25, 2022

Study contacts

Ying T Han
Contact
hanying1568@126.com
+8613661013288

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion